Bringing Medication-Free Options to Patients of Panic Disorders with Joe Perekupka and Dr. Robert Cuyler

 

PTSD affects 6.1-9.2% of the adult US population (Up To Date). Additionally, an estimated 4.7% of adults will experience a panic disorder in their lifetime (NIMH). Unfortunately, both disorders have high rates of becoming chronic and require difficult treatment programs and medications with adverse side effects.  

On this episode of Highway to Health, David Kemp talks to Joe Perekupka, CEO of Freespira, and Dr. Robert Cuyler, Chief Clinical Officer of Freespira, to discuss mental health and the drive behind Freespira’s drug-free PTSD treatments.   

Both guests apply habits to maintain mental wellness; they exercise their bodies to calm their minds. Dr. Cuyler distills it into “three ingredients, exercise, connection, and purpose. These are the three things that keep me grounded.” When treating trauma, depression, anxiety, panic disorders, and PTSD, a great deal of information is available on medication and exposure therapy. Unfortunately, each has massive downsides. 

Dr. Cuyler noted, “the challenge is using treatments that are hard to tolerate.” Even when executed well, exposure therapy is challenging for a patient to complete. The guests cite a recent study that found that about half of the people admitted to exposure therapy studies did not finish the treatment.   

The other common path—medication—has a broad spectrum of results. Drugs have varying degrees of effectiveness from person to person and take a long time to reach the desired effect. Medications also have a vast range of known and unknown side effects. “Once the patient stops these medications, there’s a huge relapse in their symptoms coming back again,” said Perekupka. These factors are critical for the founding of Freespira and its mission. Listen to the entire podcast now. 

Follow us on social media for the latest updates in B2B!

Image

Latest

private equity
Alts Innovators: UT Austin’s Dr. Ken Wiles on Private Equity
December 15, 2025

Private equity is entering a period of adjustment after decades of expansion fueled by falling interest rates and abundant capital. That long-running tailwind reversed beginning in 2022, when interest rates rose sharply, disrupting deal activity, slowing exits, and bringing renewed attention to a long-standing vulnerability in private markets: liquidity. Industry reports have highlighted softer fundraising,…

Read More
SPD
Getting SPD Teams to the Table: Why Sterile Processing Deserves a Central Role in Surgical Planning and Operations
December 15, 2025

Sterile Processing Departments (SPDs) remain the backbone of safe surgical care, yet across the country, they’re still routinely left out of early decision-making around products, construction, staffing, and case planning. As hospitals juggle tighter margins, higher patient acuity, and growing procedural demands, the consequences of excluding SPD voices become unmistakably real—showing up in daily…

Read More
WireXpert
WireXpert MP Wire Mapping Overview
December 13, 2025

In modern network installations, speed alone isn’t enough—precision is what keeps systems reliable and downtime low. Tools like the WireXpert MP cable certifier reflect how far copper cable diagnostics have evolved, moving beyond simple pass-or-fail testing into actionable insight. By running a full 500 MHz sweep on a Category 6A link, technicians can…

Read More
Why Connectivity Has Become the Cornerstone of Modern Industrial Automation
December 11, 2025

Industrial automation is in the middle of a profound shift, as manufacturers push beyond basic control toward fully connected, data-driven operations that bridge the plant floor and the enterprise. What began years ago as early experiments in digital transformation—simply getting PLC data into IT systems—has now accelerated into a critical business imperative fueled by…

Read More